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Modern diagnostic methods enable clinicians to look be-
yond a diagnosis of chronic Q fever and discern whether 
patients instead have persistent focalized Coxiella burnetii 
infection(s). Use of these methods and development of cri-
teria to define and treat such infections, especially cardio-
vascular infections, will improve the prognosis for patients 
previously thought to have chronic Q fever.
We read with interest the article by Kampschreur et al. (1), which in our opinion conveys a perspective 
that is incorrect concerning the diagnostic algorithm and 
treatment of Q fever. Kampschreur et al.’s article character-
izes the understanding and management of Q fever by the 
Dutch Q Fever Consensus Group. However, this consensus 
opinion may be erroneous if developed without input from 
disease experts with long clinical experience.
Kampschreur et al.’s use of the term chronic Q fever is 
misleading because it may lead to inadequate treatment of per-
sistent focalized Coxiella burnetii infection(s). The obsolete 
term chronic Q fever should be abandoned to prevent confu-
sion between endocarditis, vascular infections, osteoarticular 
infections, lymphadenitis, genital infection, and pericarditis, 
which occurred in 68%, 20%, 7%, 6%, 3%, and 1%, respec-
tively, of 494 patients with persistent focalized infection(s) 
who we followed during 2007–2015 at the French National 
Referral Center for Q Fever in Marseille, France (unpub. data).
Another example of the deleterious effect of the Dutch Q 
Fever Consensus Group guidelines is the absence of screen-
ing echocardiography in the standard work-up for patients 
with Q fever in the Netherlands (2). Because endocarditis 
has been reported in patients with clinically silent, undiag-
nosed valvulopathies (3), we recommend systematic echo-
cardiography for all persons with acute Q fever. Endocarditis 
develops in most untreated Q fever patients who have exten-
sive valvulopathy; however, Million et al. (4) showed that it 
did not develop in patients who received prophylaxis. This 
finding led us to recommend prophylaxis for acute Q fever 
patients with valvulopathy at the French National Referral 
Center for Q Fever; over the past 10 years, this strategy has 
reduced the incidence of Q fever endocarditis in patients at 
the center (5). Despite these observations, which were con-
firmed in the Netherlands in 2015 (6), the standard work-up 
for Q fever patients in that country has not included screen-
ing echocardiography since 2010 (2), leaving patients with 
clinically silent valvulopathy untreated.
Specific defining criteria for endocarditis (7) are needed 
to enable comparison of clinical series. Use of the term chron-
ic to define cardiovascular infections in patients with Q fever 
is misleading. Indeed, valvular vegetations were recently re-
ported in acute Q fever (8). Q fever vascular infections must 
be distinguished in the context of mycotic aneurisms, small 
saccular and embolic consequences of endocarditis that may 
go unnoticed, and underlying vascular disease. Positron emis-
sion tomography (PET) scanning has been used effectively 
in the Netherlands to systematically detect the localization of 
infection in patients with elevated serologic test results (9). 
PET scanning dramatically improves the diagnosis of cardio-
vascular infections (10). However, because the Dutch criteria 
lack clinical relevance (7), many cases of endocarditis were 
missed, and diagnoses of vascular infection were retained 
in the presence of mycotic aneurysms. These misdiagnoses 
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explain the low proportion of endocarditis cases compared 
with vascular infections in the Dutch series (15% vs. 36%, as 
reported by Kampschreur et al. (1)) compared with the series 
in our center (68% vs. 20%; unpub. data).
Endocarditis and vascular infections, whose first symp-
toms may be fatal decompensation or stroke, can be prevented 
in Q fever patients by implementing systematic screening 
echocardiography, phase I IgG monitoring, and PET scanning 
of patients with vascular disease (10). In our experience, only 
1 patient with uncontrolled Q fever endocarditis has died since 
2006, when we began following this protocol (3). The patient 
had a cardiac valve replacement 1 year before dying, but his 
phase I IgG titer was low (1:200), and C. burnetii PCR for his 
valve was negative, so no treatment was prescribed.
Reanalysis of the Q fever literature by different teams 
has brought challenging concepts to light (7). In a series from 
the Netherlands (1), 4 patients were shown to have died from 
endocarditis and 2 from vascular infections. These patients 
may have had better outcomes if the methods we propose 
here had been followed. Conversely, high serologic titers are 
not definite proof of persistent focalized infection, as illus-
trated in an outbreak in French Guiana, where exceptionally 
high serologic titers have been observed, but persistent focal-
ized infections have rarely been diagnosed (10).
Accurate identification of persistent focalized C. bur-
netii infections will improve patient outcomes by preventing 
long-term, organ-specific, lethal complications (e.g., vascu-
lar infections are a risk for vascular rupture, lymphadenitis 
is a risk for lymphoma) and by avoiding drug side effects in 
patients with isolated elevated serologic test results. Clini-
cians should look beyond a diagnosis of chronic Q fever to 
determine whether a patient might have persistent focalized 
infection(s). The term fever in Q fever has evolved from a 
pathologic picture per se to a clinical epiphenomenon; it is 
now time to evolve from the concept of chronic Q fever to 
one of persistent focalized C. burnetii infection(s) (10).
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